Filing Details
- Accession Number:
- 0001140361-16-088121
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-11-29 20:34:03
- Reporting Period:
- 2016-11-25
- Filing Date:
- 2016-11-29
- Accepted Time:
- 2016-11-29 20:34:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1197355 | J Henry Fuchs | C/O Biomarin Pharmaceutical Inc. 770 Lindaro St. San Rafael CA 94901 | President, Worldwide R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-11-25 | 15,000 | $26.49 | 128,878 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-11-25 | 15,000 | $87.40 | 113,878 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to buy Common Stock) | Disposition | 2016-11-25 | 15,000 | $0.00 | 15,000 | $26.49 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 35,225 | 2011-11-12 | 2021-05-11 | No | 4 | M | Direct |
Footnotes
- Trade made pursuant to a 10b5-1 plan executed on May 12, 2016.
- The price in column 4 is the weighted average price. The price actually received ranged from $86.67 to $88.06. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Reflects the number of stock options outstanding after the transaction from this specific stock option grant.
Billionaire Hedge Funds
